Relan A.
Geregistreerde transacties bij 1 onderneming · 48 uur vertraagd.
17Transacties
0Open-marktkopen
24-03-2022Eerste transactie
Transacties
| Gemeld | Bedrijf | Rol | Categorie | Waarde |
|---|---|---|---|---|
| 18-03-2026 | Pharming Group N.V. | Chief Medical Officer | Optie-uitoefening | 0 EUR |
| 18-03-2026 | Pharming Group N.V. | Chief Medical Officer | Optie-uitoefening | 0 EUR |
| 01-12-2025 | Pharming Group N.V. | Chief Medical Officer | Open-marktverkoop | 136.037 EUR |
| 03-09-2025 | Pharming Group N.V. | Chief Medical Officer | Optie-uitoefening | 0 EUR |
| 03-09-2025 | Pharming Group N.V. | Chief Medical Officer | Optie-uitoefening | 320.625 EUR |
| 03-09-2025 | Pharming Group N.V. | Chief Medical Officer | Open-marktverkoop | 421.875 EUR |
| 17-03-2025 | Pharming Group N.V. | Chief Medical Officer | Administratief | 0 EUR |
| 17-03-2025 | Pharming Group N.V. | Chief Medical Officer | Administratief | 0 EUR |
| 20-03-2024 | Pharming Group N.V. | Vice President, Clinical Research and Medical Affairs | Optie-uitoefening | 0 EUR |
| 20-03-2024 | Pharming Group N.V. | Vice President, Clinical Research and Medical Affairs | Toekenning | 0 EUR |
| 16-08-2023 | Pharming Group N.V. | Chief Medical Officer | Open-marktverkoop | 199.735 EUR |
| 09-08-2023 | Pharming Group N.V. | Chief Medical Officer | Optie-uitoefening | 0 EUR |
| 09-08-2023 | Pharming Group N.V. | Chief Medical Officer | Optie-uitoefening | 369.000 EUR |
| 09-08-2023 | Pharming Group N.V. | Chief Medical Officer | Open-marktverkoop | 508.500 EUR |
| 24-03-2023 | Pharming Group N.V. | Vice President, Clinical Research and Medical Affairs | Optie-uitoefening | 0 EUR |
| 24-03-2023 | Pharming Group N.V. | Vice President, Clinical Research and Medical Affairs | Toekenning | 0 EUR |
| 29-03-2022 | Pharming Group N.V. | Vice President, Clinical Research and Medical Affairs | Optie-uitoefening | 0 EUR |
Deze pagina toont uitsluitend openbare registerdata (AFM MAR art. 19). Er worden geen externe persoonsgegevens toegevoegd of gecombineerd (AVG). Zie de methodologie en over & disclaimer.